CPRX News and Press, Catalyst Pharmaceuticals Inc. From 04/08/20

Safety of personnel, patients and healthcare providers remains our top priority   Drug supply remains well-stocked with patients having access to uninterrupted supply of Firdapse® (amifampridine) 10mg   Catalyst partners with First Responders Children’s Fo...

With the Dow Jones Industrial Average , the  Nasdaq Composite Index , and the  S&P 500 all down by more than 20% from their recent highs, there's no doubt that the COVID-19 pandemic has pushed U.S. stock markets into bear territory. What's more, the social distancing measures bei...

While all are hunkered down with the ongoing Coronavirus pandemic, we are getting calls from investors looking for opportunities to deploy cash held on the sidelines or to invest profits from successful short investments. We have seen our stock portfolio take a hit as well despite some hedges ...

The coronavirus pandemic has been bad news for nearly every type of asset class in 2020. On the flip side, this indiscriminate wave of selling has undoubtedly created some amazing buying opportunities for long-term investors. Biotech stocks, for instance, were particularly hard hit by the market...

Image source: The Motley Fool. Catalyst Pharmaceuticals Inc   (NASDAQ: CPRX) Q4 2019 Earnings Call Mar 17, 2020 , 8:30 a.m. ET Operator Continue reading

Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2019 Earnings Conference Call March 17, 2020 08:30 AM ET Company Participants Alicia Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Daniel Brennan - Chief Commercial Officer Steven Miller - Chief ...

BioNTech SE (NASDAQ: BNTX ) +55%  on teaming up with Pfizer teams to develop COVID-19 vaccine. More news on: BioNTech SE, Co-Diagnostics, Inc., Neon Therapeutics, Inc., Stocks on the move, , Read more ...

Catalyst Pharmaceuticals (NASDAQ: CPRX ): Q4 GAAP EPS of $0.07 misses by $0.03 . More news on: Catalyst Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...

-Firdapse ® Q4 Net Revenues of $30 Million, FY 19 Net Revenues of $102 Million -GAAP Net Income of $32 Million for Fiscal Year 2019 -Catalyst Reiterates Net Revenue Guidance in the Range of $135 Million to $155 Million for FY 2020 -Firdapse Supply Chain in Solid...

CORAL GABLES, Fla., March 10, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologi...